Clinical trials: Solid Tumor, Adult
Solid Tumor, Adult
To Assess the Effects of Single Dose of JMKX001899 on QTc Interval in Healthy Subjects
Study to assess the effect of JMKX001899 on QTc interval in healthy volunteers
- Trial name
- NCT06473948
- Testing
- JMKX001899
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Jemincare
EBV-induced Lymphomas, EBV-associated Malignancies
Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
The purpose of this phase I/II trial is to study the side effects and best dose of biological therapy to treat patients at high-risk or with Epstein-Barr virus-associated lymphoma or lymphoproliferative disease.
- Conditions
- EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma
- Trial name
- NCT00002663
- Testing
- Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Atara Biotherapeutics
Adult Solid Tumor
Study of LTC004 in Subjects With Advanced Malignant Tumors
This was a multicenter, open, multi-cohort PHASE I study, consisting of 2 phases: Phase Ia (Phase Ia dose escalation) and Phase Ib (Phase Ib multi-cohort expansion).
- Trial name
- NCT05666635
- Testing
- LTC004
- Volunteers
- 368 people
- Sponsor
- Letolab
Solid Tumor
Dose Escalation Study of ARQ 736 in Adult Subjects With Advanced Solid Tumors Harboring BRAF and/or NRAS Mutations
This is an open-label, Phase 1, dose escalation study of oral ARQ 736 administered to subjects with advanced solid tumors harboring the mutation.
- Trial name
- NCT01225536
- Testing
- ARQ 736
- Where
- 4 sites in United States, Italy
- Volunteers
- 24 people
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Solid Tumor, Adult
3D011-08 Monotherapy in Subjects With Advanced Solid Tumors
The purpose of this study is evaluate the the safety, tolerability, pharmacokinetics profiles, and preliminary efficacy of 3D011-08 in subjects with advanced solid tumors.
- Trial name
- NCT05099536
- Testing
- 3D011-08
- Where
- China
- Sponsor
- 3D Medicines (Beijing) Co., Ltd.
Solid Tumor, Adult
A Phase l Study of By101298, an Oral DNA-PK Inhibitor, in Patients With Advanced Solid Tumors
BY101298 is an innovative DNA-dependent protein kinases (DNA-PK) highly selective small molecule inhibitor. DNA-dependent protein kinases (DNA-PK plays a key role in the NHEJ repair pathway to repair DNA double-strand breaks…
- Trial name
- NCT06462716
- Testing
- BY101298 Capsules
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Chengdu Baiyu Pharmaceutical Co., Ltd.
Cancer
Safety Study of Pharmacokinetics of XL888 in Adults With Solid Tumors
The purpose of this study is to evaluate the safety and tolerability of XL888 in subjects with solid tumors. XL888 is a potent and selective inhibitor of HSP90, a key component of a molecular chaperone complex that promotes the…
- Trial name
- NCT00796484
- Testing
- XL888
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- Exelixis
Solid Tumor, Adult
Combination of Gatipotuzumab and Tomuzotuximab in Patients With Solid Tumors
This was a single arm phase Ib study to evaluate the safety and efficacy of combined Tomuzotuximab and Gatipotuzumab therapy in patients with metastatic solid tumors expressing EGFR for whom no standard treatment is available.
- Trial name
- GATTO (NCT03360734)
- Testing
- First part: Gatipotuzumab and Tomuzotuximab; Second part: Gatipotuzumab and Tomuzotuximab or anti-EGFR antibody (Cetuximab, Panitumumab or Necitumumab)
- Where
- 4 sites in Germany, Italy and 1 more
- Volunteers
- 50 people
- Sponsor
- Glycotope GmbH
Advanced Solid Tumors, Lymphomas
A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced Solid Tumors or Lymphomas
The purpose of this study was to determine the safety profile, maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and to characterize the pharmacokinetic (PK) profile of alisertib twice daily (BID) dosing for 7 days…
- Trial name
- NCT01512758
- Testing
- Alisertib
- Where
- Singapore
- Volunteers
- 36 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Solid Tumor, Adult
Absorption and Excretion of Oral Docetaxel
This is an open-label, phase I study to investigate the influence of the bi-daily weekly dosing of ModraDoc006/ritonavir on the absorption and excretion of docetaxel in patients with advanced solid tumours.
- Trial name
- NCT05242926
- Testing
- ModraDoc006/r
- Where
- Netherlands
- Sponsor
- Modra Pharmaceuticals
HER2 Expressing Breast or Gastric/Stomach Cancers
A Phase 1/2 Study of MEDI4276 in Adults Subjects With Select HER2-expressing Advanced Solid Tumors.
This research study is designed to evaluate an experimental drug, MEDI4276, in treating breast and stomach (gastric) cancer.
- Trial name
- MEDI4276 (NCT02576548)
- Testing
- MEDI4276
- Where
- 5 sites in United States
- Volunteers
- 47 people
- Sponsor
- MedImmune LLC
Solid Tumor
To Evaluate the Safety, Pharmacokinetic and the Effect of Food After Administration of ABN401 in Healthy Adult Volunteers
This randomized open-label, two-way crossover study is designed to evaluate the safety and pharmacokinetic characteristics of ABN401, and the effect of high-fat meal on the pharmacokinetic profiles of ABN401 and its metabolites…
- Trial name
- NCT05248074
- Testing
- High-fat meal (over 900 kcal), ABN401 (investigational product)
- Where
- South Korea
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Abion Inc
Unspecified Adult Solid Tumor, Protocol Specific
3-AP Plus Cisplatin and Paclitaxel in Treating Patients With Advanced or Metastatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00016874
- Testing
- cisplatin, paclitaxel, triapine
- Where
- 2 sites in United States
- Sponsor
- Vion Pharmaceuticals
Solid Tumors
Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab
This study will be conducted in 5 parts (Parts A, B, C, D and E). Monotherapy Treatment: Subjects ≥18 years with advanced solid tumors will be enrolled in the study. Monotherapy dose escalation will be performed in Part A.
- Trial name
- NCT02628574
- Testing
- TRX518 monotherapy, TRX518 with gemcitabine, TRX518 with pembrolizumab
- Where
- 6 sites in United States
- Volunteers
- 109 people
- Sponsor
- Leap Therapeutics, Inc.
Solid Tumors
JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
This study is to evaluate the efficacy and safety of JAB-30355 in adult participants with advanced solid tumors harboring TP53 Y220C mutation.
- Trial name
- NCT06386146
- Testing
- JAB-30355
- Where
- 15 sites in United States, China
- Volunteers
- 144 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
Unspecified Adult Solid Tumor, Protocol Specific
BMS-247550 in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of BMS-247550 in treating patients who have advanced solid…
- Trial name
- NCT00004927
- Testing
- ixabepilone
- Where
- 2 sites in United States
- Sponsor
- R-Pharm
Cancer, Lymphoma
A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced Malignancies
The purpose of this study is to determine a safe dose of XL844 in combination with gemcitabine, how often it should be taken, and how well people with cancer tolerate the combination of gemcitabine and XL844.
- Trial name
- NCT00475917
- Testing
- XL844, Gemcitabine
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Exelixis
Solid Tumours
A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors
A phase 1/2a, open-label, first-in-human study mainly aimed to evaluate the safety and tolerability of BMS-986517 in participants with solid tumors
- Trial name
- NCT07160725
- Testing
- BMS-986517, Pumitamig
- Where
- 20 sites in United States, China and 3 more
- Volunteers
- 540 people
- Sponsor
- Bristol-Myers Squibb
Neoplasms
A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile
This is a multi-center, Phase 1 / 2 clinical study for patients with advanced solid tumors. The study consists of 2 treatment arms - a monotherapy arm and a combination arm.
- Trial name
- NCT03416335
- Testing
- DSP-0509, DSP-0509, Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- Sumitomo Pharma America, Inc.
Solid Tumor, Adult, Non-small Cell Lung Cancer
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or metastatic solid tumors.
- Conditions
- Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma
- Trial name
- NCT04913285
- Testing
- KIN-2787, KIN-2787 and binimetinib
- Where
- 48 sites in United States, Australia and 5 more
- Volunteers
- 400 people
- Sponsor
- Pierre Fabre Medicament